Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
H05BX01 CINACALCET ARROW BioTech Cinacalcet - 30mg 30mg Tablet, coated 8,768,039 L.L
H05BX01 CINACALCET ARROW BioTech Cinacalcet - 90mg 90mg Tablet, coated, scored 22,062,995 L.L
H05BX01 CINACALCET ARROW BioTech Cinacalcet - 60mg 60mg Tablet, coated, scored 16,494,074 L.L
L01FG02 CYRAMZA BioTech Ramucirumab - 100mg/10ml 100mg/10ml Injectable solution 47,779,251 L.L
D06BA02 CREM-O-SULFA G Sulfathiazole - 5% 5% Cream 202,216 L.L
C09AA01 CAPTACE G Captopril - 25mg 25mg Tablet, scored 486,343 L.L
C09AA01 CAPTOPRIL G Captopril - 25mg 25mg Tablet, scored 4,453,878 L.L
C09AA01 CAPTOPRIL G Captopril - 25mg 25mg Tablet, scored 355,798 L.L
R03BA02 CORTAIR G Budesonide - 1mg/2ml 0.5mg/ml Inhalation suspension for nebuliser 1,209,458 L.L
J05AB01 CYCLOVEX G Aciclovir - 200mg 200mg Tablet, scored 1,164,664 L.L
J05AB01 CYCLOVEX G Aciclovir - 400mg 400mg Tablet, scored 2,687,685 L.L
C09AA01 CAPTACE G Captopril - 50mg 50mg Tablet, scored 652,724 L.L
D06BB03 CIVAR G Aciclovir - 5% 5% Cream 507,972 L.L
A06AB07 COLON-X G Frangula Purshiana - 62.5mg, Plantago Afra - 100mg, Foeniculum Vulgare - 50mg, Zingiber Officinale - 50mg, Aniseed powder - 20mg, Glycyrrhiza Glabra - 12.5mg, Senna Alexandrina - 25mg Tablet, film coated 833,182 L.L
D06BB03 CYCLOVEX G Aciclovir - 50mg/g 50mg/g Cream 345,560 L.L
A06AB58 CITRAFLEET G Sodium picosulfate - 10mg/sachet, Magnesium oxide (light) - 3.5g/sachet, Citric acid (anhydrous) - 10.97g/sachet, Potassium - 195mg/sachet Powder for solution 1,191,988 L.L
L01XA01 CISPLATINE VIATRIS 1MG/ML G Cisplatin - 10mg/10ml 10mg/10ml Injectable concentrated solution 412,655 L.L
L01XA01 CIPINTU G Cisplatin - 50mg/50ml 50mg/50ml Injectable concentrated solution 1,206,771 L.L
D06BX01 CUTIDERMINE G Metronidazole - 1% 1% Gel 593,850 L.L
J01BA01 CHLORAMPHENICOL PALMITATE G Chloramphenicol (palmitate) - 125mg/5ml 125mg/5ml Suspension 159,981 L.L
L01XA01 CISPLATINE VIATRIS 1MG/ML G Cisplatin - 50mg/50ml 50mg/50ml Injectable concentrated solution 1,179,655 L.L
J01BA01 CHLORAMPHENICOL G Chloramphenicol - 250mg 250mg Capsule 166,381 L.L
L01XA02 CARBOPLATIN VIANEX G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 1,277,994 L.L
L01XA02 CARBOPLATINE EBEWE G Carboplatin - 150mg/15ml 150mg/15ml Injectable concentrated solution 2,691,717 L.L
N06BX03 CEBROTONIN G Piracetam - 800mg 800mg Tablet, film coated 577,852 L.L
L01XA02 CARBOPLATINE VIATRIS 10MG/ML G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 2,981,283 L.L
N06BX06 CEROLINE G Citicoline - 100mg/ml 100mg/ml Solution 894,615 L.L
L01XA02 CARPLATU G Carboplatin - 150mg/15ml 150mg/15ml Injectable solution 1,277,994 L.L
S01CA01 CO-AVAZIR G Tobramycin - 0.3%, Dexamethasone - 0.1% Drops suspension 193,513 L.L
J01DH51 CELLABAXIN G Imipenem (monohydrate) - 500mg, Cilastatin (sodium) - 500mg Injectable solution 10,699,559 L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026